Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis

Lin, Minghua; Zeng, Huamin; Deng, Guiqing; Lei, J. van der; Li, Jinxin

doi:10.1016/j.clinre.2020.08.008

Cited by 6 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…selected for detailed evaluation, four studies irrelevant to the topic and six studies with insufficient data for outcome analysis were excluded. Finally, six meta-analyses [35][36][37][38][39][40] including 2685 participants were included in the present umbrella review of meta-analyses.…”

Section: Data Synthesis and Statistical Analysismentioning

confidence: 99%

Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta‐analysis on randomized controlled trials

Wang

Prabahar

Găman

et al. 2023

J of Digest Diseases

View full text Add to dashboard Cite

ObjectiveThe impact of vitamin E supplementation on liver biomarkers in NAFLD patients remains controversial. Therefore, we conducted the present umbrella meta‐analysis of randomized controlled trials to clarify the effects of vitamin E administration on alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma‐glutamyl transferase (GGT), steatosis levels and fibrosis score in individuals diagnosed with NAFLD.MethodsFour databases (PubMed/MEDLINE, Scopus, EMBASE, and Web of Science) were searched to identify pertinent papers published in international scientific journals from the inception of these search services and up to June 2023. To calculate the overall effect size (ES) and confidence intervals (CI), we applied the random‐effects model.ResultsIn total, 6 meta‐analyses were included in the umbrella meta‐analysis. By pooling ES based on the random‐effects model, we discovered that vitamin E supplementation significantly decreased ALT (ES = −6.47 U/L; 95% CI: −11.72, −1.21, P = 0.01), AST (ES = −5.35 U/L; 95% CI: −9.78, −0.92, P = 0.01), fibrosis score (ES = −0.24 U/L; 95% CI: −0.36, −0.11, P < 0.001), and steatosis levels (ES = −0.66; 95% CI: −0.88, −0.45, P < 0.001) but had no effect on GGT values in NAFLD patients. In the subgroup analyses, we detected that fibrosis scores notably decreased when vitamin E dosage was >500 IU/day (ES = −0.25; 95% CI: −0.40, −0.09, P = 0.002) and when the treatment duration was >20 months (ES = −0.26; 95% CI: −0.47, −0.063, P = 0.01).ConclusionsVitamin E administration reduces ALT, AST, fibrosis and steatosis levels in NAFLD subjects. Fibrosis scores are significantly reduced when vitamin E dose exceeds 500 IU/day and treatment duration surpasses 20 months.This article is protected by copyright. All rights reserved.

show abstract

Section: Data Synthesis and Statistical Analysismentioning

confidence: 99%

Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta‐analysis on randomized controlled trials

Wang

Prabahar

Găman

et al. 2023

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

“…However, vitamin E has not shown significant effects on fibrosis in these patients. 102,103 Emerging therapeutics of MAFLD Multiple drugs targeting different aspects of MAFLD have been developed in the past 15 years, aiming to reduce fatty acid accumulation, inflammation, and fibrosis. However, many of these drugs are still in development or have failed to show improvement.…”

Section: Sodium-glucose Cotransporter 2 Inhibitors (Sglt2i)mentioning

confidence: 99%

Obesity and Metabolic Dysfunction-associated Fatty Liver Disease: Understanding the Intricate Link

Vulchi,

Suryadevara,

Mohan

et al. 2023

J Transl Gastroenterol

View full text Add to dashboard Cite

Obesity is a complex disease resulting from excessive adipose tissue in the body, leading to various metabolic, mechanical, and psychological complications. The prevalence of obesity has increased exponentially in the past few decades to reach an epidemic proportion. Obesity can predispose to or aggravate the fatty liver. Metabolic dysfunction-associated fatty liver disease (MAFLD) represents fatty liver in individuals who are either overweight/obese, or have type 2 diabetes, or have normal weight with at least two metabolic risk factors. MAFLD pathogenesis is multifactorial and involves an interplay of genetics, lifestyle-related factors, gut dysbiosis, lipotoxicity, and oxidative stress. Besides hepatic complications, MAFLD also has systemic implications in the form of increased risk for various metabolic diseases, cardiovascular diseases, malignancies, and infectious diseases. If left untreated, MAFLD can progress to liver cirrhosis and end-stage liver disease. Many noninvasive strategies like serum-based markers and imaging help diagnose MAFLD at an early stage. Timely detection and appropriate intervention are crucial for preventing its progression to advanced liver disease and hepatocellular carcinoma. Though lifestyle modification remains the main pillar of management, with advances in the treatment of obesity, newer agents are being tried for patients with MAFLD. The current therapeutic strategies are limited, and future research is needed to identify the subset of patients with MAFLD who are at a higher risk of hepatic and systemic complications and to develop more effective and personalized therapies.

show abstract

Regulation of gut microbiota by vitamin C, vitamin E and β-carotene

Shen

et al. 2023

Food Research International

View full text Add to dashboard Cite

Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis

Cited by 6 publications

References 23 publications

Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta‐analysis on randomized controlled trials

Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta‐analysis on randomized controlled trials

Obesity and Metabolic Dysfunction-associated Fatty Liver Disease: Understanding the Intricate Link

Regulation of gut microbiota by vitamin C, vitamin E and β-carotene

Contact Info

Product

Resources

About